BMS pulls new diabetes med in Germany

Share this article:

Bristol-Myers Squibb and AstraZeneca chased Thursday's warm-and-fuzzy FDA panel endorsement news of its type 2 diabetes medication with a splash of cold water Friday when they announced they were pulling the drug from the German market, where it is known as Forxiga (dapagliflozin). The companies said they have not had agreeable pricing discussions with local insurers and are walking away.

The drug's Dec. 13 endorsement was a redemption of sorts—an FDA panel turned the drug makers away in 2001 over safety concerns. Briefing documents indicated that reviewers were still worried about bladder cancer.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.